Takeda establishes development center in China

Friday, February 10, 2012 09:54 AM

Takeda Pharmaceutical has established the Takeda Shanghai Development Center ("TSDC") within the Shanghai-based Takeda (China) Holdings (TCH), a wholly owned subsidiary of Takeda.

The step reflects Takeda's strategic commitment to Asia and to China in particular. Takeda is now enhancing its business in China through TCH's wholly owned subsidiaries, Takeda Pharmaceutical (China) in Taizhou, responsible for manufacturing, and Tianjin Takeda Pharmaceuticals in Tianjin, responsible for marketing and sales. With them, TSDC will help drive Takeda's growth agenda in China and in the broader Asian region.

Within Asia outside Japan, including China, drug development is overseen by Takeda Global Research & Development Center (Asia) in Singapore and Millennium Pharmaceuticals in Cambridge, Mass., wholly owned subsidiaries of Takeda, through outsourcing to CROs. TSDC will work to extend the company's clinical development activities within Asia, with a focus on China for general medicine and across Asia for Oncology. The team will be composed of personnel from both the Pharmaceutical Development Division and Millennium.

Share:          
CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs